Conclusion
myelotoxicity
METASTATIC COLORECTAL CANCER
Biweekly trifluridine/tipiracil, irinotecan, and bevacizumab administration may have moderate antitumor activity with high risk of severe myelotoxicity in previously treated patients with metastatic colorectal cancer [UMIN Clinical Trials Registry (UMIN000019828) and Japan Registry of Clinical Trials (jRCTs041180028)].In this phase Ib study, MODURATE, efficacy and safety of trifluridine/tipiracil, irinotecan, and bevacizumab was tested in patients with metastatic colorectal cancer with fluoropyrimidine and oxaliplatin treatment failure